发布时间：2026-05-22 09:10 Precemtabart tocentecan (Precem-TcT) is investigated as a potential first-in-class anti-CEACAM5 ADC, for the treatment of metastatic CRC (mCRC)
CEACAM5 is overexpressed in the majority of colorectal tumors (~90%), and requires no patient selection
Significant unmet need remains for clinically meaningful innovation in colorectal cancer (CRC), the second leading cause of cancer death worldwide
Not intended for Canada-, UK- or US-based media



DARMSTADT, Germany--(BUSINESS WIRE)--Merck, a leading science and technology company, today announced that the first patient has been dosed in the Phase 3 PROCEADE®-CRC-03 trial (NCT07549412). The study is evaluating precemtabart tocentecan (PrecemTcT), a potential firstinclass investigational antiCEACAM5 antibodydrug conjugate (ADC), for the treatment of metastatic colorectal cancer (mCRC).

“Leveraging our novel payloadlinker technology, PrecemTcT is the first CEACAM5targeted ADC in
=*=*=*=*=*=
当前为第1/10页
下一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页